leon-nanodrugs secures funds in a series D financing to broaden portfolio in first single-use high throughput production systems for nanoencapsulation
2024年8月6日 - 5:00PM
leon-nanodrugs GmbH (LEON), a pharmatech company specializing in
the development of nanoencapsulation systems for genetic material
and other active substances, announced today the closing of a
Series D financing round. New lead investor LBBW Venture Capital
closed the round together with new investors and existing
shareholders like Albany Private Equity Holdings Pty Ltd.,
CD-Venture GmbH, Eckenstein-Geigy-Stiftung, Signet Healthcare
Partners, TVM Life Science Innovation I L.P., and others.
“I am very pleased that we have completed this
financing in the planned amount. The new funds will be used to
augment the product portfolio. Our portfolio of leading equipment
is designed to serve the Cell & Gene Therapy industry, enabling
highly economic GMP manufacturing of small and individualized
batches of nanoencapsulated Cell & Gene Therapies. Together
with the financing, this puts us in a good position to select the
best possible strategic partner to bring those products to the
market,” commented Christian Nafe, Managing Director & CFO
of LEON.
LEON’s strongly differentiated systems offer
significant USP’s filling current industry gaps:
- |
|
NANOscreen |
bench-top system for simplified formulation screening |
- |
|
NANOlab® |
bench-top system for fast and efficient process development |
- |
|
NANOme® |
aseptic production system for high throughput small- and
individualized-scale GMP manufacturing requiring no cleaning
and sterilization due to a single use component |
- |
|
NANOus® |
large scale production unit for commercial, sterile GMP
batches. |
The underlying FR-JET® reactor technology is
prepared for future versatility of carrier material, and is
optimized for minimal batch losses, and no scaling out. It is
included in all NANO-systems allowing to seamlessly scale up from
process development to commercial manufacturing.
Dr. Frank Mühlenbeck, representing lead investor
LBBW Venture Capital, will join LEON’s Supervisory Board. He
stated: “LEON’s products allow the efficient development and
production of new, upcoming modalities in the biopharma industry
including LNP’s with a special focus on decentralized
patient-specific treatments. In addition to this bench-to-bedside
approach, LEON’s products also empower CDMOs offering centralized
manufacturing of such treatments. We completely understand the
industry need for next-generation manufacturing solutions and are
glad to support LEON in their effort to advance their products to
commercialization.”
Dr. Hubert Birner, Managing Partner at TVM Life
Science Management and Chairman of LEON’s Supervisory Board stated:
“As a long-standing investor in LEON, we welcome the investment of
LBBW VC, as it comes at a pivotal time for LEON to facilitate use
of our lead products in the market. While medicine of today
embraces more and more Cell & Gene Therapies, a smart solution
for cost-efficient, fast and yet reliable and safe manufacturing is
still required.”
ABOUT
LEON-NANODRUGSleon-nanodrugs GmbH (LEON) has developed
ground-breaking technology solutions tailored for nanocarrier
production. Central to LEON’s cutting-edge equipment is the
proprietary nanoencapsulation technology, the FR-JET® system,
setting the gold standard in efficiency and reliability. With a
commitment to revolutionizing the pharmaceutical industry, LEON’s
portfolio enables a streamlined pathway to clinical batches,
ensuring rapid progression from development to production,
facilitating fast and efficient access to personalized medicine,
globally. Whether catering to individual-level dosing or
large-scale commercial needs, LEON’s solutions are engineered to
deliver optimal results at every stage. For further information,
please visit https://leon-nanodrugs.com/ and follow us on
LinkedIn.
ABOUT LBBW VCLBBW VC was
founded in 1998 as an independent subsidiary of the Landesbank
Baden-Württemberg and invests in disruptive IT and life science
companies in the DACH region with a passion for entrepreneurs and
their ideas.
CONTACT: |
MEDIA INQUIRIES: |
leon-nanodrugs
GmbHChristian Nafe (Managing Director & CFO,
consultant to the company)Phone:
+49-89-414248890Email: info@leon-nanodrugs.com |
MC Services AGKatja Arnold / Eva BauerPhone:
+49-89-210228-0Email: leon-nanodrugs@mc-services.eu |